共被期刊论文引用了5次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Impact of prophylactic/preemptive donor lymphocyte infusion and intensified conditioning for relapsed/refractory leukemia:a real-world study显示文摘Prophylactic/preemptive donor lymphocyte infusion(p/pDLI)and intensified conditioning have shown promising results in experimental studies of refractory/relapsed acute leukemia(RRAL),but real-world data remain scarce.We conducted a multicenter,population-based analysis of 932 consecutive patients.The three-year leukemia-free survival(LFS)rates were 56%for patients receiving both p/pDLI and intensified myeloablative conditioning(MAC)(intenseMAC)and 30%for those who received neither therapy per landmark analysis.Multivariable analyses were run separately for acute myeloid leukemia(AML)and acute lymphoblastic leukemia(ALL),and p/pDLI treatment was linked to significantly higher LFS than non-DLI for both AML and ALL patients without increasing the nonrelapse mortality.IntenseMAC was associated with significantly lower relapse and higher LFS than nonintensified MAC despite higher nonrelapse mortality rates in ALL,while there was no impact of intenseMAC observed in AML.p/pDLI achieved superior outcomes in both matched-sibling donor(MSD)and haploidentical donor transplantation,while intenseMAC only influenced MSD outcomes.Data suggest that RRAL patients receiving“total therapy”by way of p/pDLI and intensified conditioning treatment have an improved chance for LFS,with p/pDLI being safer with a more extensive impact relative to intenseMAC.Patients with RRAL can tolerate both interventions and achieve a reasonable outcome. | Yu Wang Qi-Fa Liu De-Pei Wu Jing-Bo Wang Xi Zhang Heng-Xiang Wang Feng Gao Shun-Qing Wang Zi-Min Sun Jian Ouyang Kai-Lin Xu Su-Jun Gao Lan-Ping Xu Chen-Hua Yan Xiao-Jun Huang | 2020 | Science China(Life Sciences)2020，63，10： | 3 |
| 2 | 异基因造血干细胞移植治疗儿童急性淋巴细胞白血病中国专家共识(2022年版)显示文摘急性淋巴细胞白血病(ALL)是儿童时期最常见的恶性肿瘤,目前儿童ALL患者5年总生存率(OS)已超过90%,仍有部分患儿表现为难治或复发,预后不良[1-5]。二代测序技术(NGS)、新型靶向药物、新型免疫治疗等诊疗手段不断应用于临床,但异基因造血干细胞移植(allo-HSCT)仍是治疗儿童难治/复发ALL的有效手段[6]。 | 中华医学会血液学分会干细胞应用学组 中华医学会儿科学分会 黄晓军 吴德沛 王天有 张晓辉 程翼飞 郑胡镛 张乐萍 | 2022 | 中华血液学杂志2022，43，10： | 2 |
| 3 | 企业信息技术规划模型——走向因特网显示文摘本文针对信息技术的急剧发展的现状 ,考虑到企业在信息技术的投资、选择上的困惑和无序 ,通过一个渐进的IT规划模型 ,为面向21世纪的企业因特网生存提供一个决策模型。 | 郑伟平 | 2000 | 技术经济与管理研究2000，，2： | 2 |
| 4 | Adaptive T cell immunotherapy in cancer显示文摘Impaired tumor-specific effector T cells contribute to tumor progression and unfavorable clinical outcomes. As a compensatoryT cell-dependent cancer immunoediting strategy, adoptive T cell therapy (ACT) has achieved encouraging therapeutic results,and this strategy is now on the center stage of cancer treatment and research. ACT involves the ex vivo stimulation and expansionof tumor-infiltrating lymphocytes (TILs) with inherent tumor reactivity or T cells that have been genetically modified to expressthe cognate chimeric antigen receptor or T cell receptor (CAR/TCR), followed by the passive transfer of these cells into alymphodepleted host. Primed T cells must provide highly efficient and long-lasting immune defense against transformed cellsduring ACT. Anin-depth understanding of the basic mechanisms of these living drugs can help us improve upon currentstrategies and design better next-generation T cell-based immunotherapies. From this perspective, we provide an overview ofcurrent developments in different ACT strategies, with a focus on frontier clinical trials that offer a proof of principle. Meanwhile,insights into the determinants of ACT are discussed, which will lead to more rational, potent and widespread applicationsin the future. | Dongdong Ti Miaomiao Bai Xiaolei Li Jianshu Wei Deyun Chen Zhiqiang Wu Yao Wang Weidong Han | 2021 | Science China(Life Sciences)2021，64，3： | 2 |
| 5 | 微小残留病指导的急性淋巴细胞白血病免疫干预和治疗策略显示文摘白血病微小残留病(minimal residual disease,MRD)是指白血病患者经过诱导化疗或骨髓移植获得血液学完全缓解(hematologic complete remission,HCR)后,体内残存的形态学上不能检测到的少量白血病细胞。MRD可用于急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)的疗效评估,尤其是被用于复发预警、治疗方法的选择以及复发干预的指导。近年来,免疫干预和治疗逐渐成为恶性血液病治疗的热点。该文概述了ALL患者MRD的检测方法和意义,重点讨论并提出了MRD指导的ALL免疫干预和治疗策略。 | 常英军 王玥雯 | 2023 | 现代免疫学2023，43，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员